Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Shorted: Short Interest Down 37.2% in September

Posted by Anthony Miller on Oct 2nd, 2026

Artelo Biosciences, Inc. (NASDAQ:ARTL – Get Free Report) was the recipient of a large drop in short interest in the month of September. As of September 15th, there was short interest totaling 22,550 shares, a drop of 37.2% from the August 31st total of 35,918 shares. Based on an average trading volume of 45,211 shares, the short-interest ratio is currently 0.5 days. Approximately 4.3% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Artelo Biosciences in a research report on Monday, September 21st. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Reduce”.

Read Our Latest Stock Report on ARTL

Artelo Biosciences Stock Performance

ARTL stock opened at $3.83 on Friday. Artelo Biosciences has a one year low of $3.45 and a one year high of $179.19. The firm’s 50 day moving average price is $6.01 and its 200-day moving average price is $19.77. The firm has a market cap of $2.11 million, a PE ratio of -0.03 and a beta of -0.07.

Artelo Biosciences (NASDAQ:ARTL – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($6.48) by $5.59.

About Artelo Biosciences

(Get Free Report)

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the endocannabinoid system, a network of receptors and signaling pathways involved in processes such as pain, inflammation, appetite and immune response. The company is headquartered in San Diego, California, and its research and development activities are directed toward pharmaceutical applications of cannabinoid biology rather than consumer cannabis products.

Artelo’s pipeline has included ART27.13, a peripherally restricted cannabinoid receptor agonist being evaluated for conditions associated with appetite loss and cancer-related cachexia.